Research map: Valuation of Medical Innovation in Orphan Diseases with a Focus on Small Investors and Limited Diversifiable Risks

Back to the article

Papers in this map

  1. Innovation in the pharmaceutical industry: New estimates of R&D costs · Joseph A. DiMasi · 2016 · 3386 citations · Cited by this paper
  2. Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada · 2026 · Related
  3. The Capital Asset Pricing Model: Theory and Evidence · Eugene F. Fama · 2004 · 1952 citations · Cited by this paper
  4. Joint Clinical Assessment in the EU HTA Regulation—Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? · 2026 · Related
  5. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment · Michael Schlander · 2021 · 368 citations · Cited by this paper
  6. Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency · 2026 · Related
  7. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 · Thomas J. Moore · 2018 · 367 citations · Cited by this paper
  8. Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development Strategies · 2026 · Related
  9. The $2.6 Billion Pill — Methodologic and Policy Considerations · Jerry Avorn · 2015 · 330 citations · Cited by this paper
  10. Analysis of How the Term “Shall” Is Understood and Applied to the EU-HTA Regulation · 2026 · Related
  11. Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy · Mohamed Abou‐El‐Enein · 2021 · 321 citations · Cited by this paper
  12. Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy · 2026 · Related
  13. Assessing the economic challenges posed by orphan drugs · Michael Drummond · 2007 · 280 citations · Cited by this paper
  14. Primary Care or Primary Problem? Aligning Access Pathways with Patient Needs Across the Care Continuum · 2026 · Related
  15. Real options, irreversible investment and firm uncertainty: New evidence from U.S. firms · Laarni Tobia Bulan · 2005 · 239 citations · Cited by this paper
  16. Comparative Cost Evaluation of Managed Entry Agreement Techniques Using Real-World Data from High-Cost Anticancer Drugs in Thailand · 2026 · Related
  17. Irreversible investment, real options, and competition: Evidence from real estate development · Laarni Tobia Bulan · 2008 · 224 citations · Cited by this paper
  18. Direct Public-Payer Costs of Dialysis Therapies in Greece: A Patient-Level Micro-Costing Study Across Modality and Provider Sector · 2026 · Related
  19. Risk Uncertainty and Supply Chain Decisions: A Real Options Perspective · G. Tomas M. Hult · 2010 · 214 citations · Cited by this paper
  20. EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making · 2025 · Related
  21. Demythologizing the high costs of pharmaceutical research · Donald W. Light · 2011 · 213 citations · Cited by this paper
  22. Clinical development times for innovative drugs · Dean G. Brown · 2021 · 177 citations · Cited by this paper
  23. Risk-Neutral Pricing Approach for Evaluating BOT Highway Projects with Government Minimum Revenue Guarantee Options · Baabak Ashuri · 2011 · 175 citations · Cited by this paper
  24. Application of real options analysis for pharmaceutical R&D project valuation—Empirical results from a survey · Marcus Hartmann · 2006 · 161 citations · Cited by this paper
  25. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials · Seshu Tyagarajan · 2019 · 161 citations · Cited by this paper
  26. What Is Wrong with Orphan Drug Policies? · André C. Côté · 2012 · 111 citations · Cited by this paper
  27. A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan Medicines · Jon Sussex · 2013 · 110 citations · Cited by this paper
  28. Establishing a reasonable price for an orphan drug · Mikel Berdud · 2020 · 78 citations · Cited by this paper
  29. Innovation and Marketing in the Pharmaceutical Industry · Min Ding · 2013 · 77 citations · Cited by this paper
  30. In search of innovative techniques to evaluate pharmaceutical R&D projects · William F. Jacob · 2003 · 67 citations · Cited by this paper
  31. Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results · Stephanie Rennane · 2021 · 47 citations · Cited by this paper
  32. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios · Thomas F. Broekhoff · 2021 · 45 citations · Cited by this paper
  33. Uncertainty and Industry Structure Effects on Managerial Intuition About Information Technology Real Options · Nancy K. Lankton · 2008 · 44 citations · Cited by this paper
  34. Real Options and Strategic Investment Decisions: Can They Be of Use to Scholars? · Charlotte Krychowski · 2010 · 43 citations · Cited by this paper
  35. Managers’ Incorporation of the Value of Real Options into Their Long‐Term Investment Decisions: An Experimental Investigation* · Christine A. Denison · 2011 · 32 citations · Cited by this paper
  36. New estimates of the cost of capital for pharmaceutical firms · Carmelo Giaccotto · 2011 · 23 citations · Cited by this paper
  37. Optimizing Commercial Manufacturing of Tisagenlecleucel for Patients in the US: A 4-Year Experiential Journey · Margarida Rodrigues · 2021 · 19 citations · Cited by this paper
  38. Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation · S. Sean Tu · 2023 · 17 citations · Cited by this paper
  39. The impact of early phase price agreements on prices of orphan drugs · Mark J. C. Nuijten · 2021 · 14 citations · Cited by this paper

Source: OpenAlex (CC0)